All News
1/600 Falls May Die (4.5.2024)
Dr. Jack Cush reviews the news and Journal reports from this past week on RheumNow.com - including problems w/ falls, pain and treatment of Dupuytren’s contractures.
Read Article
ICYMI: Top 5 Clinical Pearls in RA Management
RheumNow Live 2024 provided a wealth of clinical insights, particularly in the realm of rheumatoid arthritis (RA) management. Here are the top five clinical pearls from the event's opening session, "Success in Rheumatoid Arthritis."
Read Article
Serious Infections in Takayasu arteritis
The large vessel vasculitis, Takayasu arteritis (TAK), carries a significant morbid risk and a cohort analysis shows these patients are also at high risk of serious infection with resultant higher risk of death.
Pearl: 40% of acute gout attacks will have a normal serum uric acid (that will elevated during intercritical phase) - Draw the lab during and after the attack. https://t.co/CynZOal9jc
Dr. John Cush RheumNow ( View Tweet)
Neuropsychiatric (NP) Sxs compared in SLE (n 609), controls (463) & IA patients (489).
Hallucinations and severe headache were most directly attributable to NP-SLE. https://t.co/JWbyHmpWcq https://t.co/gBubdEjq63
Dr. John Cush RheumNow ( View Tweet)
337 PMR pts studied by FDG PET, followed 6 mos - 9% (31) had subclinical vasculitis (GCA)
- 21 had isolated LG vessel
- 3 isolated cranial vasculitis
- 7 both cranial & LG vessel vasculitis.
Steroid use higher w/ subclinical vasculitis, but not relapse https://t.co/uwXf4ucVnQ https://t.co/AOacTnQZaS
Dr. John Cush RheumNow ( View Tweet)
How do you communicate risk/benefit to patients? @RADoctor's recent publication highlighted by Dr. H. Gabalawy at #RNL2024
-Increase awareness
-Include numbers for context
- Make it easy for patients to understand those numbers
-Use absolute risks
- Avoid 1 in X format
Dr. John Cush RheumNow ( View Tweet)
Aging in RA: "(RA is due to a poorly functioning immune system which increases a patients risk of CVD, infection, and cancer. The aging immune system additionally affects this process.
Dr. John Cush RheumNow ( View Tweet)
We must consider this clinically, we must protect our aging patients without over immunosuppressing them." Dr. Weyand #RNL2024
Dr. John Cush RheumNow ( View Tweet)
H2H study of secukinumab vs adalimumab biosimilar in axial-SpA pts saw no difference & little change in Xray progression for both Rxs. 859 pts showed no signif diff w/ NO Xray progr (66%, 67%, 66%) or mSASSS (0.54, 0.55, 0.72) change https://t.co/QqB1aCjfN7 https://t.co/Ktfi7xVoC6
Dr. John Cush RheumNow ( View Tweet)
Polycyclic Aromatic Hydrocarbons Increase Lupus Risk
A case-controlled study shows environmental exposure to polycyclic aromatic hydrocarbons (PAH) may increase the risk of developing systemic lupus erythematosus (SLE).
https://t.co/kztA4s5UY3 https://t.co/QJ6DXXCBh8
Dr. John Cush RheumNow ( View Tweet)
We're back again on 4/9 with another Tuesday Night Rheumatology! We'll be focusing on PsA Hot Topics. Register to attend today!
https://t.co/Ssbv020MOi https://t.co/qL6EGegCVf
Links:
Dr. John Cush RheumNow ( View Tweet)
10 SLE pts w/ ITP and thrombocytopenia were Rx w/ belimumab IV (age 34.3 ± 14 yrs). Overall response rate of thrombocytopenia was 90%, w/ improvement in platelets, lymphocyte count, Hgb, dsDNA, C3, C4 and SLEDAI https://t.co/0IXjqXa8lS https://t.co/pNiu4TCnky
Dr. John Cush RheumNow ( View Tweet)
Among 3.2 million people who starting opioids, there were 506 573 serious fall, esp w/ increasing age; Opioid use associated with increased risk of serious falls, esp. if >85 yrs (adj IRR 6.35) and within the first 28 days of commencing opioid use https://t.co/IifmEE9Q5n https://t.co/N2PkLofA4r
Dr. John Cush RheumNow ( View Tweet)
Oral Surveillance study revisited: the risk of Venous thromboembolism & Pulmonary emboli were higher with tofacitinib (10>5 mg BID) versus TNFi and were generally consistent over time. VTE & PE risk incr by age, BMI, and VTE Hx https://t.co/v7ISjw5Rvd https://t.co/10oE7MiAAj
Dr. John Cush RheumNow ( View Tweet)
"#RNL2024
Brittany Weber on Cardio-Rheumatology:
""Everything has changed"" on inflammation and CVD
- Canakinumab 150 mg v PBO HR 0.85, p =0.02
- Colchicine v PBO HR 0.69, P<0.001
2023: FDA approval for colchicine as 1st anti-inflammatory for reducing CV events
Dr. John Cush RheumNow ( View Tweet)
#RNL2024 @RheumNow
@Bweber04
Asymptomatic Lupus has higher rate of atherosclerosis at all age grps
35-44 yo F with SLE: 50X increased risk of MI compared to healthy pts in Framingham
RA pts at 1.5x risk of CVD https://t.co/wL4U8Gh5JM
Links:
Dr. John Cush RheumNow ( View Tweet)
#RNL2024
ASCVD Risk Calculators underestimate risk in patients of RA
Inflammatory disease was added as a "risk enhancer" in 2019 update
"A low ASCVD and/or absence of symptoms may be not be reassuring" https://t.co/Cz1LRda9xx
Links:
Dr. John Cush RheumNow ( View Tweet)
13 Risk Factors for RA-associated Interstitial Lung Disease (ILD)
ILD is the most widespread and fatal pulmonary complication of rheumatoid arthritis (RA). A recent metanalysis shows the pooled prevalence of RA-ILD was approximately 18.7%.
https://t.co/oqb37RWPuZ https://t.co/tp3qBh1wRC
Dr. John Cush RheumNow ( View Tweet)
Pearl: Three "S" Rule (Smoking, Seropositivity, Sex/Male): if present the risk of RA-UIP (ILD) goes up nearly 13 fold (ACR23 Abstract 1269) https://t.co/heiTtarS1Y https://t.co/EkHbmMgIEC
Dr. John Cush RheumNow ( View Tweet)